Skip to content Skip to footer
Subscribe Now
Biopharma M&A Top 20 2024
TOP 20

Top 20 Biopharma M&A of 2024 by Total Deal Value

Top 20 Biopharma M&A of 2024 by Total Deal Value Shots: Dealmaking in 2024 experienced fluctuations due to regulatory challenges and increasing pressure from the Inflation Reduction Act The highest-value deal of the year was Vertex’s acquisition of Alpine Immune Sciences for $4.9B, followed by Gilead’s acquisition of CymaBay for $4.3B and Lilly’s acquisition of…
February 6, 2025

Read more

Know Your Investor: Orbimed (February’ 25 Edition)
INSIGHTS+

Know Your Investor: Orbimed (February’ 25 Edition)

Shots:    The February edition highlights OrbiMed Advisors, a New York-based investment firm specializing in public and private investments within the healthcare and biotech sectors  In 2024, OrbiMed expanded its portfolio by adding 49 companies, investing approximately $6.08B across five funding rounds, including private and debt financing  For the complete report, contact us at connect@pharmashots.com  OrbiMed primarily…
February 6, 2025

Read more

New Drug Designations - December 2024
INSIGHTS+

New Drug Designations – December 2024

Shots:   PharmaShots' designation report provides a concise overview of the latest drug designations by major regulatory authorities, including the FDA, EMA, MHLW and NMPA   The December 2024 report covers designations granted to 43 drugs and 3 devices, encompassing 13 small molecules, 10 biologics, 7 cell and gene therapies & 3 medical devices among others  Significant…
January 31, 2025

Read more

Know Your Investor RA Capital Management (January’25 Edition)
INSIGHTS+

Know Your Investor: RA Capital Management (January’25 Edition)

Shots:    The January Edition features RA Capital Management, a global multi-stage investment firm dedicated to healthcare and life sciences  In 2024, RA Capital added 74 companies to its portfolio, investing approximately $8.5B across seven funding rounds, including private and common funding  Welcome to the 2025 series of Know Your Investor, a meticulously crafted report highlighting…
January 16, 2025

Read more

NEWS

J.P. Morgan Special: Dealmaker of the Year 2024 (Part 02)

Shots: In this second installment of Dealmaker 2024, PharmaShots presents an insightful guide to the top M&A deals ranked by deal value This report highlights Novo Nordisk’s remarkable achievements, including 24 collaborations spanning acquisitions, company formations, contract services, development and commercialization agreements, facility purchases, licensing options, and platform/product purchases. Collectively, these deals amount to…
January 15, 2025

Read more

J.P. Morgan Special: Dealmaker of the Year 2024 (Part 02)
INSIGHTS+

J.P. Morgan Special: Dealmaker of the Year 2024 (Part 02)

Shots:   In this second installment of Dealmaker 2024, PharmaShots presents an insightful guide to the top M&A deals ranked by deal value This report highlights Novo Nordisk’s remarkable achievements, including 24 collaborations spanning acquisitions, company formations, contract services, development and commercialization agreements, facility purchases, licensing options, and platform/product purchases. Collectively, these deals amount to a…
January 15, 2025

Read more

NEWS

J.P. Morgan Healthcare Conference Special: Dealmaker of the Year 2024 (Part 01)

Shots: The first dose of the J.P. Morgan Special: Dealmaker of the Year report based on the total number of deals signed in 2024 Last year, Roche inked 38 deals comprising acquisitions, contract services, development & commercialization, facility purchase, R&D, platform/product purchases, and sales/co-promotion Leveraging DealForma’s invaluable insights, PharmaShots brings an on-demand report…
January 8, 2025

Read more

J.P. Morgan Healthcare Conference Special: Dealmaker of the Year 2024 (Part 01)
INSIGHTS+

J.P. Morgan Healthcare Conference Special: Dealmaker of the Year 2024 (Part 01)

Shots:  The first dose of the J.P. Morgan Special: Dealmaker of the Year report based on the total number of deals signed in 2024  Last year, Roche inked 38 deals comprising acquisitions, contract services, development & commercialization, facility purchase, R&D, platform/product purchases, and sales/co-promotion   Leveraging DealForma’s invaluable insights, PharmaShots brings an on-demand report on the Dealmaker…
January 8, 2025

Read more

Load more